ArticlePatient preference and adherence2026
Development and Validation of the Medication Adherence Scale for Iraqi Patients with Rheumatoid Arthritis (MASIPRA): A Cross-Sectional Study.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adherence to disease-modifying anti-rheumatic drugs (DMARDs) is essential to ensure optimum benefit for rheumatoid arthritis (RA) patients. However, adherence to DMARDs was suboptimal worldwide, especially in developing countries like Iraq. Many adherence scales are available to help healthcare providers assess RA patients' adherence to their prescribed therapies; however, such tools are often generic, lengthy, unavailable in Arabic, or not freely accessible. Objective: To develop and validate the Medication Adherence Scale for Iraqi Patients with Rheumatoid Arthritis (MASIPRA) and examine its psychometric properties. Methods: The Medication Adherence Scale for Iraqi Patients with Rheumatoid Arthritis was developed based on previously validated scales with cultural adaptation. It consists of ten items rated on a 5-point Likert scale. Content validity of MASIPRA was done by a panel of seven experts. Clarity of the scale items was established through testing on ten RA patients. Reliability of MASIPRA was confirmed through testing internal consistency (Cronbach's alpha) and test-retest reliability. Convergent validity was established by correlating the total MASIPRA score with an already validated scale, the Morisky Medication Adherence Scale-4 (MMAS-4). Concurrent validity was confirmed by correlating the MASIPRA score with the RA clinical disease activity index (CDAI). Results: MASIPRA showed good internal consistency (Cronbach's alpha=0.804) and test-retest reliability (r=0.804, p< 0.001). It was strongly and significantly correlated with MMAS-4 (r=0.863, p< 0.001) and significantly but inversely correlated with CDAI (r = -0.278, p=0.005). Compared with the MMAS-4, the MASIPRA showed higher sensitivity and specificity in discriminating RA patients according to their disease activity. Conclusion: The MASIPRA is a brief, reliable, and valid instrument for assessing adherence to DMARDs among Iraqi patients with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.